

## A systematic investigation of the permeability of androgen receptor PROTACs

Duncan E. Scott, Timothy P.C. Rooney, Elliott D. Bayle,<sup>†,‡</sup> Tashfina Mirza, Henriette M.G. Willems, Jonathan H. Clarke, Stephen P. Andrews, John Skidmore\*

ALBORADA Drug Discovery Institute, University of Cambridge, Island Research Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0AH, United Kingdom

<sup>†</sup>Alzheimer's Research UK UCL Drug Discovery Institute, The Cruciform Building, University College London, Gower Street, London, WC1E 6BT, United Kingdom

<sup>‡</sup>The Francis Crick Institute, 1 Midland Road, Kings Cross, London, NW1 1AT, UK

*KEYWORDS: PROTACs, drug discovery, androgen receptor, medicinal chemistry*

**ABSTRACT:** Bifunctional molecules known as PROTACs simultaneously bind an E3 ligase and a protein of interest to direct ubiquitination and clearance of that protein, and have emerged in the last decade as an exciting new paradigm in drug discovery. In order to investigate the permeability and properties of these large molecules, we synthesised two panels of PROTAC molecules, constructed from a range of protein-target ligands, linkers and E3 ligase ligands. The androgen receptor, which is a well-studied protein in the PROTAC field was used as a model system. The physicochemical properties and permeability of PROTACs is discussed.

**KEYWORDS:** PROTACs, permeability, cell activity, androgen receptor

Chemically-induced, targeted protein degradation is an emerging pharmacological strategy for manipulation of intracellular protein levels.<sup>1</sup> One way this has been achieved is through the design of bifunctional molecules that simultaneously bind to a protein of interest and an E3 ubiquitin ligase. By bringing these two proteins into proximity, PROTeolysis TARgeting Chimeras (PROTACs) facilitate the ubiquitylation and proteasomal degradation of the protein of interest. Early PROTACs relied on short peptide sequences to bind the E3 ligase protein and their low permeability necessitated microinjection into cells,<sup>2</sup> however recent identification of small molecule ligands for E3 ligases has opened the possibility of cell-permeable non-peptidic PROTACs. The ability to degrade the entire protein in a cell, rather than simply inhibit the catalytic domain, distinguishes PROTACs from traditional small-molecule inhibitors. Further, the removal of additional roles of the protein, such as complex formation and scaffolding with other proteins, means that PROTACs can access unique pharmacology. PROTACs are also potentially catalytic, each molecule can direct degradation of multiple target proteins. PROTACs have been developed for numerous protein classes, including nuclear receptors,<sup>3</sup> epigenetic factors,<sup>4</sup> and kinases.<sup>5</sup> These compounds have been used to study the effect of enforced degradation of the target protein in a number of cell lines and also in *in vivo* studies.<sup>6,7</sup> Whilst this work has the potential to offer a new pharmacological paradigm, clinical utility is yet to be demonstrated and a number of challenges still remain.<sup>8</sup> A recent *in vivo* study of a potent PROTAC (DC<sub>50</sub> 0.3 nM) indicated that despite an impressive systemic knock-down of the desired FKBP12 protein, the brain was the only tissue analysed where protein

levels were unaffected, indicating that the blood-brain barrier may intrinsically present a greater challenge to PROTACs than other biological membranes.<sup>7</sup>

PROTAC molecules are rule-breaking in respect to traditional medicinal chemistry guidelines<sup>8</sup>; they possess high molecular weight and high TPSA.<sup>9</sup> Permeability is key for activity against intracellular targets and in general, permeability drops off drastically with increasing molecular weight yet despite this, some impressive cell potencies for PROTACs have been reported.<sup>6</sup> Other classes of small-molecules, also beyond the rule of 5, have been reported to have high cell permeability and oral bioavailability.<sup>10</sup> Notably, cyclic peptides and natural products such as rifamycins are thought to adopt conformations that allow formation of intramolecular hydrogen bonds, reducing the effective polarity of the molecules and allowing passage through membranes.<sup>11, 12</sup> We hypothesised that in a similar fashion, it might be possible for PROTAC molecules to possess rule-breaking permeability, either by linker-mediated conformational collapse in water, or by the two functional ends of the PROTAC migrating through a membrane in a pseudo-independent fashion by virtue of the length and flexibility of the linker so disguising their high molecular volume. PROTAC molecules are typically composed of two rigid protein-binding small molecules, connected by a linker. As we focus on flexible linkers in this work, further linker types with more rigidity remain to be explored. Recently Foley *et al* have published observations on permeability using a chloroalkane penetration assay, focusing on the permeability of a chloroalkane modified BRD4 PROTAC.<sup>13</sup> A wider study to evaluate the impact of linker, protein-ligand and E3 ligase ligand on the permeability of PROTACs is warranted.

In our study, the androgen receptor (AR) was selected as a model system. A panel of selective AR modulators (SARMs) have previously been developed, and many PROTACs for the AR protein have also been reported, employing a variety of E3 ligase ligands.<sup>2, 3, 14, 15</sup> As such it is a de-risked, well-studied system. The AR is a DNA-binding transcription factor nuclear hormone receptor that, through binding to the endogenous ligand testosterone, mediates growth factor and cell-signalling dependent gene expression. The ligand binding domain (LBD) provides a defined binding pocket for endogenous steroidal ligands including testosterone. A number of SARMs are in clinical trials for a variety of indications.<sup>14, 16</sup> Furthermore, polyglutamine expansion of the AR causes the neuromuscular disease spinal and bulbar muscular atrophy (SBMA or Kennedy's disease).<sup>17</sup> A PROTAC designed to catalyse the degradation of this neurotoxic form of AR could offer a strategy for intervention in this disease.





Figure 1: (A) AR ligand **2** in complex with AR ligand binding domain (pdb id: 3v49). The linker attachment point is circled in red. (B) Structures of compounds **1-5**, derived from AR ligands, for incorporation into PROTACs. The linker attachment point is indicated in red. (C) Proteolysis directing groups **6-9**, the attachment point when incorporated into PROTACs is indicated in blue. (D) Lenalidomide bound to Cereblon E3 ubiquitin ligase (pdb id: 4ci2). The linker attachment point is circled in blue. (E) General AR PROTAC structure of PROTAC Sets 1 and 2.

In designing a set of PROTACs, the three components of the PROTAC molecule were systematically varied; the AR ligand, the E3 ubiquitin ligase ligand and the linker region. To select suitable ligands for the AR, SARMS were identified that were predicted to have good CNS permeability using MPO scoring.<sup>18</sup> SARMS **1-5** all bind in the LBD of the AR, Figure 1A. An analysis of the binding modes of available crystal structures reveals SARMS present a similar vector to exit the AR binding site, in a position that has been successfully exploited by previously reported AR PROTACs.<sup>3</sup> The structures of AR ligands **1-5** are shown in Figure 1B. SARM **1** is a close analogue of the clinical compounds andarine and ostarine. The hydantoin SARM **2** possesses high affinity for AR ( $EC_{50}$  1.6 nM).<sup>19</sup> The thiohydantoin derivative **3** has been developed into the clinical compound enzalutamide, and incorporated into PROTACs.<sup>20</sup> Pyrrolidine-based SARM **4** represents a very ligand-efficient class of modulators, of which Ligandrol is a compound in clinical development.<sup>21</sup> The cyclobutane SARM **5** has also been previously reported.<sup>22</sup>

X-ray crystal structures of SARMS bound to AR reveal the ligand completely enclosed by helix 12 (Figure 2A). In order for AR PROTACs to bind and the linker to exit the AR protein, some protein conformational change must occur. Gryder *et al.* have previously reported a set of AR-binding bifunctional molecules that also bind histone deacetylases (HDAC), and suggests that helix 12 (H12) forms a 'lid' over SARMS, that can move to accommodate extended AR ligands.<sup>23</sup> Indeed, the related estrogen receptor (ER) demonstrates large changes in the conformation of H12 when bound to an antagonist,<sup>24</sup> hence we created a homology model of the AR with an H12-open conformation, based upon an H12-open ER protein complex (Figure 2B and


Supporting Information). Docking PROTACs into this model successfully reproduced the binding mode of the SARM, and allowed the linker to extend past H12 into the solvent, permitting a rational design of linker length and linker-SARM attachment points.



**Figure 2** (A) Helix 12 (H12, red) of AR protein (pdb id: 2pnu) occludes the entrance to the ligand-binding domain. The docked small molecule **3b** (Figure S1) is indicated by green spheres. (B) A homology model of AR with helix-12 in an open conformation (red helix) was generated. The re-modelled helix 12 allows access from the ligand-binding domain to the bulk solvent, and accommodation of PROTAC linkers.

Only a limited number of E3 ligases have been targeted by PROTAC molecules, though recent studies have focused on expanding the repertoire.<sup>25</sup> We employed 4 different proteolysis targeting groups **6-9**, with distinct physicochemical properties (Figure 1C). The immunomodulatory drugs thalidomide, and analogues pomalidamide and lenalidomide, have been identified as ligands of the E3 ligase Cereblon (Figure 1D), and structural analogues **6** and **7** have been successfully incorporated into PROTACs.<sup>26</sup> Small-molecule ligands of the von Hippel Lindau (VHL) E3 ligase such as **9**, have also been developed and incorporated into PROTACs.<sup>4-6</sup> Another approach to chemically target protein degradation has been to covalently<sup>27</sup> or non-covalently<sup>28</sup> associate a hydrophobic tag with a protein and thus promote its clearance. It has been suggested in the context of AR clearance, that the presentation of the hydrophobic adamantane moiety **8** on the AR surface is recognised as unfolded protein by the Hsp70/CHIP system, leading to AR clearance.<sup>28</sup>

For the first half of this work, a focused set of PROTACs (PROTAC Set 1, Figure 1E and S2) was synthesised by linking AR ligands and smaller E3 ligands with a PEG linker (**10-19**, Scheme S3 and S4), predicted by calculations to have a neutral effect on the logD (Figure S4). In the second half of the study, a further set of compounds (PROTAC Set 2, Figure 1E and S3) focused on the VHL E3 ligase was synthesised (**20a-i**, Scheme S6). In this set, the linker composition was varied to evaluate the impact of linker of permeability and functional activity. Fluorine was also incorporated into the linker, which has not been reported in PROTAC linkers previously. The effects of addition of fluorine may be wide-ranging, potentially altering properties such as the electrostatics of the linker, interaction with proteins, linker conformation,<sup>29</sup> permeability and microsomal stability. All PROTAC structures are shown in full in the SI (Figure S2 and S3).




**Figure 3:** Structure, biophysical properties and biological activities of PEG-linked PROTAC Set 1. Coloring is added to aid visualization. (a) The general structure of a set of PROTACs (**10-19**, Set 1) is shown in the top left, comprised of AR ligands **1-4**, E3 ligase ligands **6-8** and a PEG-linker. The PAMPA permeability for compounds **1-4** and **6-8** are shown in the outer edge of the table. The main body of the table shows the PROTAC compound number in bold (**10-19**), composed from AR ligand **1-4** and E3 ligase ligand **6-8**, followed by PAMPA permeability. The same table format is used in (b)-(d). BLQ = Below limit of quantification (b) HSA % free determined by HPLC and as described in methods section (c) chromLogD<sub>7.4</sub> determined by HPLC as described in methods section.




With both sets of PROTACs in hand, the PEG-linked PROTACs (Set 1: **10-19**, Figure 3) and the linker-varied VHL set (Set 2: **20a-i**, Table 2), a panel of ADMET parameters was selected for their potential to impact cell activity; passive permeability (PAMPA), human serum albumin (HSA) binding and chromLogD<sub>7.4</sub>. PROTACs **10-19** (Set 1, Figure 3) represent a model set of PROTACs with physicochemical properties that minimise molecular weight and TPSA and are not atypical to other PROTACs in terms of these parameters. The chosen AR ligands are small and potent, the E3 ligase ligands have low molecular weight and the PEG-linker represents a typical reasonable linker length and distribution of polar atoms.<sup>3,22</sup> The PAMPA Papp for the AR ligands gives a wide range of permeability; low for ligand **1** ( $1.4 \times 10^{-6} \text{ cm s}^{-1}$ ) and high for ligand **4** ( $13.3 \times 10^{-6} \text{ cm s}^{-1}$ ) (Figure 3A). Given the reported activity of PROTACs in the literature, reasonable permeability for this PROTAC set might be expected, especially when combining the most permeable AR ligand and E3 ligase ligand. However, almost without exception, the permeability of the final PROTAC molecules in the PAMPA assay was very low and below the limit of quantification (Figure 3A and Table 2). It is apparent that the high molecular weight and high TPSA, which is intrinsic to PROTAC molecules, is driving poor permeability for this class of molecules in this assay. Recovery in the PAMPA assay was moderate, i.e. 40-80% in most cases (Table S2). Of note is PROTAC **19**, which combines ligandrol derivative **4** and adamantyl degron **8**, and has a PAMPA permeability of  $2.3 \times 10^{-6}$

cm s<sup>-1</sup>, the highest PAMPA permeability measured for our bifunctional molecules (Figure 3C). The high logD for this PROTAC, a feature of PROTACs with the lipophilic adamantyl head-group, presumably contributes to the moderate permeability.

Given the low passive permeabilities measured in the PAMPA assay, we also tested a selection of PROTAC molecules for bidirectional permeability in Caco-2 cells (Table 1 and Table 2). Briefly, this more biologically relevant assay uses a polarised monolayer of Caco-2 cells and hence allows assessment of permeability in two opposing directions ('A2B' and 'B2A'), also permitting an assessment of active transport from the ratio of directional permeabilities.<sup>30</sup> Typical thresholds for permeability classification are; low < 1.0 x 10<sup>-6</sup> cm s<sup>-1</sup>, medium 1-5 x 10<sup>-6</sup> cm s<sup>-1</sup>, high > 5 x 10<sup>-6</sup> cm s<sup>-1</sup>.<sup>31</sup> Whilst Caco-2 permeability is a useful measurement, in particular to predict oral bioavailability, inference of efflux ratios in other cell types may be complicated by different transporter profiles in different cell types.<sup>32</sup>

**Table 1: Summary of PAMPA and Caco-2 permeability of selected PROTACs with varying proteolysis directing groups**



	E3 ligase ligand	PAMPA <sup>a</sup>	Caco-2 A2B <sup>a</sup>	Caco-2 B2A <sup>a</sup>	Caco-2 ER <sup>b</sup>
<b>14</b>		< 1.0	1.7	14.1	8.4
<b>18</b>		< 1.0	0.15	0.22	1.5
<b>20d</b>		< 1.0	< 0.69	8.6	> 12

<sup>a</sup>Permeability / 10<sup>-6</sup> cm s<sup>-1</sup>; <sup>b</sup> Efflux Ratio.

From the Caco-2 data it is possible to make comparisons to discern the effect of the E3 ligase ligand in the context of AR ligand **3** and a PEG-linker (Table 1). Interestingly, cereblon ligand-containing PROTAC **14** has the best A2B permeability measured at 1.7 x 10<sup>-6</sup> cm s<sup>-1</sup>. The B2A rate is high for this compound, 14.1 x 10<sup>-6</sup> cm s<sup>-1</sup>, clearly indicating that transporter efflux is an issue (efflux ratio = 8.4). Replacing the cereblon ligand with the small, hydrophobic adamantane degron in PROTAC **18** leads to a 10-fold decrease in A2B and a 64-fold decrease in B2A (0.15 and 0.22 x 10<sup>-6</sup> cm s<sup>-1</sup> respectively) and no evidence of transporter efflux (ER = 1.5). Substituting with the larger, more polar VHL ligand in PROTAC **20d** gives an A2B permeability below the limit of quantification for this compound, but as the B2A rate is 9.6 x 10<sup>-6</sup> cm s<sup>-1</sup>, it is evident that an efflux issue is present (ER > 12).



The effect of the linker on Caco-2 permeability was explored with a set of PROTACs from Set 2 (VHL ligand containing PROTACs) (Table 2). For the PROTACs studied, A2B could either be quantified as low (<1.0 x 10<sup>-6</sup> cm s<sup>-1</sup>), or couldn't be measured at all. Interestingly, a range of

B2A rates were observed. For PROTAC **20b**, A2B and B2A were measured as  $0.35$  and  $0.24 \times 10^{-6} \text{ cm s}^{-1}$  respectively, indicating no significant transporter efflux. It is noteworthy that the linkers of PROTACs **20b**, **20c** and **20g** bearing different numbers of fluorine atoms lead to PROTACs that are all rather similar in terms of permeability; A2B and B2A rates are low. Contrastingly, PROTAC **20d** demonstrates a high sensitivity to the change to a PEG-linker, B2A is high ( $8.6 \times 10^{-6} \text{ cm s}^{-1}$ ) and the efflux ratio is high ( $> 12$ ). In summary, low passive permeability in PAMPA assays is typically observed for PROTACs, but a marked structural influence of the linker and E3 ligase ligand on A2B, B2A and efflux ratio in Caco-2 cells can be observed. The recovery of compounds in the Caco-2 assay was reasonable, 60-100% (Table S3). Of note, all PROTACs were relatively unbound to HSA protein, between 6-15% (Figure 3B and Table 2). More work is required to investigate this beyond the compound set studied here.

**Table 2: Structure, biophysical properties and permeability of VHL-targeting PROTACs (PROTAC Set 2).**

Cmpd	Linker	HSA <sup>a</sup>	logD <sup>b</sup>	PAMPA <sup>c</sup>	Caco-2 A2B <sup>d</sup>	Caco-2 B2A <sup>d</sup>	Caco-2 ER <sup>e</sup>
<b>20a</b> <sup>22</sup>		10%	6.0	< 1.0	< 2.7	1.4	> 0.5
<b>20b</b> <sup>22</sup>		9%	6.3	< 1.0	0.35	0.24	0.7
<b>20c</b>		7%	6.3	< 1.0	0.26	< 0.79	< 3
<b>20d</b>		11%	5.1	< 1.0	< 0.69	8.6	> 12
<b>20e</b> <sup>22</sup>		7%	6.2	< 1.0	ND	ND	ND
<b>20f</b>		6%	6.1	< 1.0	ND	ND	ND
<b>20g</b>		7%	6.1	< 1.0	< 0.11	0.33	> 3




Cmpd	Linker	HSA <sup>a</sup>	logD <sup>b</sup>	PAMPA <sup>c</sup>	Caco-2 A2B <sup>d</sup>	Caco-2 B2A <sup>d</sup>	Caco-2 ER <sup>e</sup>
<b>20h</b>		8%	5.8	< 1.0	ND	ND	ND
<b>20i</b> <sup>22</sup>		7%	6.7	< 1.0	ND	ND	ND

<sup>a</sup> HSA % free, determined by HPLC method; <sup>b</sup> chromLogD<sub>7.4</sub>, determined by HPLC method; <sup>c</sup> PAMPA permeability / 10<sup>-6</sup> cm s<sup>-1</sup>; <sup>d</sup> Permeability / 10<sup>-6</sup> cm s<sup>-1</sup>; <sup>e</sup> Efflux Ratio. ND = Not determined.

The biological efficacy of the PROTACs to degrade endogenous levels of the AR receptor was assessed using a Western blotting technique in LNCaP cells. LNCaP (androgen-dependent human prostate adenocarcinoma) cells are a well-characterised model for AR expression and are commonly used in AR PROTAC studies. For effective clearance, a stable tertiary complex must form and surface lysines on the target protein must be presented in the correct manner for efficient ubiquitin transfer.<sup>25</sup> Briefly, PROTAC activities can generally be described by two numbers; DC<sub>MAX</sub> is the percentage of protein clearance observed, and the DC<sub>50</sub> is the concentration required to clear half of the DC<sub>MAX</sub>. Previously reported<sup>22</sup> PROTAC **20a** was chosen as a positive control for the clearance assay, Figure 4A. In general our PROTACs displayed mostly weak (DC<sub>MAX</sub> < 30%) or no clearance effects in the cell assay (not shown). To dispense the concern that the generally poor activity observed in cells might be due to the chosen attachment points in the PROTACs preventing AR binding, representative PROTACs **20a** and **20i** were tested for AR binding using a radioligand displacement assay (Figure S5). Both PROTACs retained low nM affinity for the androgen receptor, despite the different AR ligands, different linker and the attachment of the VHL ligand. This is supportive of our docking model (Figure 2B), and indicates that the phenolic attachment point of the AR ligands in our PROTACs is compatible with AR binding *in vitro*. The amide attachment point of the VHL ligand has been well validated in other PROTAC studies.<sup>4-6</sup>

The activity data for two structurally related PROTACs, **14** and **15**, are shown in Figure 4B and serve to exemplify how small changes in PROTACs can lead to profound changes in cell activity. PROTAC **15** is active (DC<sub>MAX</sub> = 33%, DC<sub>50</sub> = 10 nM), but PROTAC **14** is inactive, despite possessing the highest A2B permeability measured, albeit with a high efflux ratio. The only structural difference between the two PROTACs is whether the E3 ligase ligand possesses a carbonyl group in the cereblon-binding moiety. Interestingly, Wang et al. have reported similar large activity differences regarding this carbonyl group in a set of BET PROTACs.<sup>33</sup> There are many reasons why PROTAC AR activity data may show idiosyncratic SAR, beyond permeability. In particular, recent papers demonstrate that in the case of cereblon-binding PROTACs, small changes in PROTAC chemical structure can significantly reduce the intended activity of a bona fide PROTAC, and induce off-target GSPT1 degradation, thereby altering the PROTAC's mode of action.<sup>34</sup>





**Figure 4** (A) AR clearance activity of previously reported<sup>22</sup> PROTAC **20a** (B) AR clearance activity of PROTAC **14** and **15**. Plots show normalised AR protein levels as a function of PROTAC concentration. PROTAC **14** is inactive in this cell assay. A minor change of the Cereblon ligand leads to higher activity of PROTAC **15**; a  $DC_{MAX}$  of 33% and a  $DC_{50}$  of 10 nM.  $N=5$  (or more) independent experiments performed in triplicate (individual data points shown). Statistical significance by ANOVA (Dunnett's) \*\*\*\* =  $p < 0.0001$ .

In summary, even our simplest PROTAC molecules formed from moderately sized linkers connecting relatively small AR ligands and E3 ligase ligands possess low PAMPA and Caco-2 A2B permeability. If this is a general observation, it is clear that PROTAC permeability, is not “rule-breaking”. Caco-2 permeability data sheds a little more light on the permeability profiles of some PROTACs and evidence of structure-dependent engagement with transport efflux proteins is observed. We recommend that Caco-2 permeability therefore, rather than PAMPA permeability, might be a more useful measurement. A recent publication from Cantrill *et al.* supports these conclusions.<sup>35</sup> Broadly, a catalytic mode of action is supported by our

permeability dataset, that sub-stoichiometric levels of PROTACs in a cell can catalyse the clearance of a target protein population. Some minimal permeability threshold for PROTACs may exist, but is likely to be much lower than is usually recognised for Rule of 5-compliant small molecules. The chemical stability of a PROTAC in a cell over time will also be important for the continued degradation of protein. Recently, methodology to measure concentrations of small molecules in cellular compartments has become increasingly utilised and has already been applied to PROTACs.<sup>36</sup> The use of this technology has emerged as a potentially useful tool to provide insights into PROTAC uptake into cells, though interpretation might be complicated by compound adhering to the outer cell membrane. To investigate the real time clearance of proteins, Riching *et al.* have recently reported methods to monitor PROTAC-induced protein degradation.<sup>37</sup> Understanding the cellular uptake of a PROTAC, its stability in the cell over time, and the kinetics of protein clearance will be critical in informing design of better PROTACs. By better understanding the connection between PROTAC structure and cellular efficacy, we will be able to rationally design better molecules and translate PROTAC molecules into the clinic more efficiently.

## **ASSOCIATED CONTENT**

### ***Supporting Information***

The Supporting Information is available free of charge on the ACS Publications website.

General experimental information; organic synthesis and compound characterization, AR affinity data, logD and HSA data and protocol, cell activity protocol, AR binding assay.

## **AUTHOR INFORMATION**

### **Corresponding Author**

\* (J.S.) E-mail: js930@cam.ac.uk

### ***Present Addresses***

TM presently at The Francis Crick Institute, 1 Midland Road, London, NW1 1AT.

### ***Author Contributions***

The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

### ***Funding Sources***

This work was funded by Alzheimer's Research UK (grant: ARUK-2015DDI-CAM), with support from the ALBORADA Trust. The ALBORADA Drug Discovery Institute is core funded by Alzheimer's Research UK (registered charity No. 1077089 and SC042474).

## **ACKNOWLEDGMENT**

The authors wish to thank Simon Edwards for synthesis of compound **2**, and David Rubinsztein for helpful discussions.

## **ABBREVIATIONS**

AR, androgen receptor; PROTACs, PROteolysis TArgeting Chimeras; PAMPA, parallel artificial membrane permeability; TPSA, total polar surface area; A2B, Apical to Basolateral; B2A, Basolateral to Apical; BLQ, Below Limit of Quantification.

## SUPPORTING INFORMATION

Chemical procedures, compound characterisation and biological protocols are detailed in Supporting Information.

1. Lai, A. C.; Crews, C. M., Induced protein degradation: an emerging drug discovery paradigm. *Nat Rev Drug Discov* **2017**, *16* (2), 101-114.
2. Schneekloth, J. S., Jr.; Fonseca, F. N.; Koldobskiy, M.; Mandal, A.; Deshaies, R.; Sakamoto, K.; Crews, C. M., Chemical genetic control of protein levels: selective in vivo targeted degradation. *J Am Chem Soc* **2004**, *126* (12), 3748-54.
3. Schneekloth, A. R.; Pucheault, M.; Tae, H. S.; Crews, C. M., Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics. *Bioorg Med Chem Lett* **2008**, *18* (22), 5904-8.
4. Zengerle, M.; Chan, K. H.; Ciulli, A., Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4. *ACS Chem Biol* **2015**, *10* (8), 1770-7.
5. Tan, L.; Gray, N. S., When Kinases Meet PROTACs. *Chinese Journal of Chemistry* **2018**, *36* (10), 971-977.
6. Bondeson, D. P.; Mares, A.; Smith, I. E.; Ko, E.; Campos, S.; Miah, A. H.; Mulholland, K. E.; Routly, N.; Buckley, D. L.; Gustafson, J. L.; Zinn, N.; Grandi, P.; Shimamura, S.; Bergamini, G.; Faeltsh-Savitski, M.; Bantscheff, M.; Cox, C.; Gordon, D. A.; Willard, R. R.; Flanagan, J. J.; Casillas, L. N.; Votta, B. J.; den Besten, W.; Famm, K.; Kruidenier, L.; Carter, P. S.; Harling, J. D.; Churcher, I.; Crews, C. M., Catalytic in vivo protein knockdown by small-molecule PROTACs. *Nat Chem Biol* **2015**, *11* (8), 611-7.
7. Sun, X. Y.; Wang, J.; Yao, X.; Zheng, W.; Mao, Y.; Lan, T. L.; Wang, L. G.; Sun, Y. H.; Zhang, X. Y.; Zao, Q. Y.; Zhao, J. G.; Xiao, R. P.; Zhang, X. Q.; Ji, G. J.; Rao, Y., A chemical approach for global protein knockdown from mice to non-human primates. *Cell Discovery* **2019**, *5*.
8. Churcher, I., Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones? *J Med Chem* **2018**, *61* (2), 444-452.
9. Edmondson, S. D.; Yang, B.; Fallan, C., Proteolysis targeting chimeras (PROTACs) in 'beyond rule-of-five' chemical space: Recent progress and future challenges. *Bioorg Med Chem Lett* **2019**, *29* (13), 1555-1564.
10. Doak, B. C.; Over, B.; Giordanetto, F.; Kihlberg, J., Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates. *Chem Biol* **2014**, *21* (9), 1115-42.
11. Agrawal, S.; Ashokraj, Y.; Bharatam, P. V.; Pillai, O.; Panchagnula, R., Solid-state characterization of rifampicin samples and its biopharmaceutic relevance. *Eur J Pharm Sci* **2004**, *22* (2-3), 127-44.
12. Matsson, P.; Kihlberg, J., How Big Is Too Big for Cell Permeability? *J Med Chem* **2017**, *60* (5), 1662-1664.
13. Foley, C. A.; Potjewyd, F.; Lamb, K. N.; James, L. I.; Frye, S. V., Assessing the Cell Permeability of Bivalent Chemical Degraders Using the Chloroalkane Penetration Assay. *ACS Chem Biol* **2020**, *15* (1), 290-295.
14. Narayanan, R.; Mohler, M. L.; Bohl, C. E.; Miller, D. D.; Dalton, J. T., Selective androgen receptor modulators in preclinical and clinical development. *Nucl Recept Signal* **2008**, *6*, e010.
15. Han, X.; Wang, C.; Qin, C.; Xiang, W.; Fernandez-Salas, E.; Yang, C. Y.; Wang, M.; Zhao, L.; Xu, T.; Chinnaswamy, K.; Delproposto, J.; Stuckey, J.; Wang, S., Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degradator of Androgen Receptor (AR) for the Treatment of Prostate Cancer. *J Med Chem* **2019**, *62* (2), 941-964.

16. Cohen, S.; Nathan, J. A.; Goldberg, A. L., Muscle wasting in disease: molecular mechanisms and promising therapies. *Nat Rev Drug Discov* **2015**, *14* (1), 58-74.
17. La Spada, A. R.; Wilson, E. M.; Lubahn, D. B.; Harding, A. E.; Fischbeck, K. H., Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. *Nature* **1991**, *352* (6330), 77-9.
18. Wager, T. T.; Hou, X.; Verhoest, P. R.; Villalobos, A., Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. *ACS Chem Neurosci* **2010**, *1* (6), 435-49.
19. Nique, F.; Hebbe, S.; Peixoto, C.; Annoot, D.; Lefrancois, J. M.; Duval, E.; Michoux, L.; Triballeau, N.; Lemoullec, J. M.; Mollat, P.; Thauvin, M.; Prange, T.; Minet, D.; Clement-Lacroix, P.; Robin-Jagerschmidt, C.; Fleury, D.; Guedin, D.; Deprez, P., Discovery of diarylhydantoins as new selective androgen receptor modulators. *J Med Chem* **2012**, *55* (19), 8225-35.
20. Crews, C. M.; Crew, A. P.; Dong, H.; Wang, J.; Qian, Y.; Siu, K.; Jin, M. Imide-based modulators of proteolysis and associated methods of use. WO/2016/197032. 2016.
21. Basaria, S.; Collins, L.; Dillon, E. L.; Orwoll, K.; Storer, T. W.; Miciek, R.; Ulloor, J.; Zhang, A.; Eder, R.; Zientek, H.; Gordon, G.; Kazmi, S.; Sheffield-Moore, M.; Bhasin, S., The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. *J Gerontol A Biol Sci Med Sci* **2013**, *68* (1), 87-95.
22. Meizhong, J.; Crew, A. P.; Dong, H.; Wang, J.; Siu, K.; Ferraro, C.; Chen, X.; Qian, Y. Compounds and methods for the targeted degradation of the androgen receptor. WO/2016/118666. 2016.
23. Gryder, B. E.; Akbashev, M. J.; Rood, M. K.; Raftery, E. D.; Meyers, W. M.; Dillard, P.; Khan, S.; Oyelere, A. K., Selectively targeting prostate cancer with antiandrogen equipped histone deacetylase inhibitors. *ACS Chem Biol* **2013**, *8* (11), 2550-60.
24. Shiau, A. K.; Barstad, D.; Loria, P. M.; Cheng, L.; Kushner, P. J.; Agard, D. A.; Greene, G. L., The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. *Cell* **1998**, *95* (7), 927-37.
25. Ottis, P.; Toure, M.; Cromm, P. M.; Ko, E.; Gustafson, J. L.; Crews, C. M., Assessing Different E3 Ligases for Small Molecule Induced Protein Ubiquitination and Degradation. *ACS Chem Biol* **2017**, *12* (10), 2570-2578.
26. Chessum, N. E. A.; Sharp, S. Y.; Caldwell, J. J.; Pasqua, A. E.; Wilding, B.; Colombano, G.; Collins, I.; Ozer, B.; Richards, M.; Rowlands, M.; Stubbs, M.; Burke, R.; McAndrew, P. C.; Clarke, P. A.; Workman, P.; Cheeseman, M. D.; Jones, K., Demonstrating In-Cell Target Engagement Using a Pirin Protein Degradation Probe (CCT367766). *J Med Chem* **2018**, *61* (3), 918-933.
27. Tae, H. S.; Sundberg, T. B.; Neklesa, T. K.; Noblin, D. J.; Gustafson, J. L.; Roth, A. G.; Raina, K.; Crews, C. M., Identification of hydrophobic tags for the degradation of stabilized proteins. *Chembiochem* **2012**, *13* (4), 538-41.
28. Gustafson, J. L.; Neklesa, T. K.; Cox, C. S.; Roth, A. G.; Buckley, D. L.; Tae, H. S.; Sundberg, T. B.; Stagg, D. B.; Hines, J.; McDonnell, D. P.; Norris, J. D.; Crews, C. M., Small-Molecule-Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging. *Angew Chem Int Ed Engl* **2015**, *54* (33), 9659-62.
29. Thiehoff, C.; Rey, Y.; Gilmour, R., The Fluorine *Gauche* Effect: A Brief History. *Israel Journal of Chemistry* **2017**, *57* (1-2), 92-100.
30. van Breemen, R. B.; Li, Y., Caco-2 cell permeability assays to measure drug absorption. *Expert Opin Drug Metab Toxicol* **2005**, *1* (2), 175-85.
31. Varma, M. V.; Gardner, I.; Steyn, S. J.; Nkansah, P.; Rotter, C. J.; Whitney-Pickett, C.; Zhang, H.; Di, L.; Cram, M.; Fenner, K. S.; El-Kattan, A. F., pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery. *Mol Pharm* **2012**, *9* (5), 1199-212.

32. Hilgendorf, C.; Ahlin, G.; Seithel, A.; Artursson, P.; Ungell, A. L.; Karlsson, J., Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. *Drug Metab Dispos* **2007**, *35* (8), 1333-40.
33. Qin, C.; Hu, Y.; Zhou, B.; Fernandez-Salas, E.; Yang, C. Y.; Liu, L.; McEachern, D.; Przybranowski, S.; Wang, M.; Stuckey, J.; Meagher, J.; Bai, L.; Chen, Z.; Lin, M.; Yang, J.; Ziazadeh, D. N.; Xu, F.; Hu, J.; Xiang, W.; Huang, L.; Li, S.; Wen, B.; Sun, D.; Wang, S., Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degradator of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression. *J Med Chem* **2018**, *61* (15), 6685-6704.
34. Yang, J.; Li, Y.; Aguilar, A.; Liu, Z.; Yang, C. Y.; Wang, S., Simple Structural Modifications Converting a Bona fide MDM2 PROTAC Degradator into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degradators. *J Med Chem* **2019**, *62* (21), 9471-9487.
35. Cantrill, C.; Chaturvedi, P.; Rynn, C.; Petrig Schaffland, J.; Walter, I.; Wittwer, M. B., Fundamental aspects of DMPK optimization of targeted protein degraders. *Drug Discov Today*, published online 13<sup>th</sup> March 2020; DOI: 10.1016/j.drudis.2020.03.012.
36. McCoull, W.; Cheung, T.; Anderson, E.; Barton, P.; Burgess, J.; Byth, K.; Cao, Q.; Castaldi, M. P.; Chen, H.; Chiarparin, E.; Carbajo, R. J.; Code, E.; Cowan, S.; Davey, P. R.; Ferguson, A. D.; Fillery, S.; Fuller, N. O.; Gao, N.; Hargreaves, D.; Howard, M. R.; Hu, J.; Kawatkar, A.; Kemmitt, P. D.; Leo, E.; Molina, D. M.; O'Connell, N.; Petteruti, P.; Rasmusson, T.; Raubo, P.; Rawlins, P. B.; Ricciuto, P.; Robb, G. R.; Schenone, M.; Waring, M. J.; Zinda, M.; Fawell, S.; Wilson, D. M., Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6. *ACS Chem Biol* **2018**, *13* (11), 3131-3141.
37. Riching, K. M.; Mahan, S.; Corona, C. R.; McDougall, M.; Vasta, J. D.; Robers, M. B.; Urh, M.; Daniels, D. L., Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action. *ACS Chem Biol* **2018**, *13* (9), 2758-2770.